Feb 14 |
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
|
Jan 12 |
IN8bio files to sell 42.7M shares for holders
|
Jan 4 |
In8bio stock jumps 11% following clinical update
|
Jan 4 |
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals
|
Dec 13 |
Why ReShape Lifesciences Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
|
Dec 11 |
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia
|
Dec 11 |
IN8bio prices its $46.9M in private placement
|
Dec 11 |
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement
|
Dec 7 |
IN8bio Appoints Dr. Corinne Epperly to Board of Directors
|
Dec 5 |
IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia
|